TWI739779B - 布魯頓氏酪胺酸激酶抑制劑及其使用方法 - Google Patents
布魯頓氏酪胺酸激酶抑制劑及其使用方法 Download PDFInfo
- Publication number
- TWI739779B TWI739779B TW105140759A TW105140759A TWI739779B TW I739779 B TWI739779 B TW I739779B TW 105140759 A TW105140759 A TW 105140759A TW 105140759 A TW105140759 A TW 105140759A TW I739779 B TWI739779 B TW I739779B
- Authority
- TW
- Taiwan
- Prior art keywords
- dihydro
- carboxamide
- thio
- triazapyrene
- methyl
- Prior art date
Links
- 0 CN(CCCCC*)CCCN Chemical compound CN(CCCCC*)CCCN 0.000 description 36
- ARNFSJMVKRTBNS-ZGZCKBCJSA-N C/C(/C(N(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O)=C\C1CC1 Chemical compound C/C(/C(N(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O)=C\C1CC1 ARNFSJMVKRTBNS-ZGZCKBCJSA-N 0.000 description 1
- XXHFALQMUFKABT-FPYGCLRLSA-N C/C=C/C(N(CCC1)CC1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)=O Chemical compound C/C=C/C(N(CCC1)CC1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)=O XXHFALQMUFKABT-FPYGCLRLSA-N 0.000 description 1
- XXHFALQMUFKABT-ZUSXEKFQSA-N C/C=C\C(N(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound C/C=C\C(N(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O XXHFALQMUFKABT-ZUSXEKFQSA-N 0.000 description 1
- ABOJLAZZHVHEOQ-UHFFFAOYSA-N C=CC(N(CCC1)CC1NC=O)=O Chemical compound C=CC(N(CCC1)CC1NC=O)=O ABOJLAZZHVHEOQ-UHFFFAOYSA-N 0.000 description 1
- ASWNOIHYBPGAKA-QGZVFWFLSA-N C=CC(N(CCC1)C[C@@H]1NC(c([s]c1c2c(N3c(ccc(Oc4ccccc4)c4)c4F)ccn1)c2NC3=O)=O)=O Chemical compound C=CC(N(CCC1)C[C@@H]1NC(c([s]c1c2c(N3c(ccc(Oc4ccccc4)c4)c4F)ccn1)c2NC3=O)=O)=O ASWNOIHYBPGAKA-QGZVFWFLSA-N 0.000 description 1
- UOYKTXKHCAUFKF-GFCCVEGCSA-N C=CC(N(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(cc3)cc(Cl)c3Cl)c11)c1NC2=O)=O)=O Chemical compound C=CC(N(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(cc3)cc(Cl)c3Cl)c11)c1NC2=O)=O)=O UOYKTXKHCAUFKF-GFCCVEGCSA-N 0.000 description 1
- KNAHXIOXKXBHIK-OAQYLSRUSA-N C=CC(N(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c3ccc(Cc4ccccc4)cc3)c11)c1NC2=O)=O)=O Chemical compound C=CC(N(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c3ccc(Cc4ccccc4)cc3)c11)c1NC2=O)=O)=O KNAHXIOXKXBHIK-OAQYLSRUSA-N 0.000 description 1
- UQCNMBASIBCHCZ-UHFFFAOYSA-N C=CC(N1CC(CNC(c([s]c2nccc(N3c(cc4)ccc4Oc4ccccc4)c22)c2NC3=O)=O)CC1)=O Chemical compound C=CC(N1CC(CNC(c([s]c2nccc(N3c(cc4)ccc4Oc4ccccc4)c22)c2NC3=O)=O)CC1)=O UQCNMBASIBCHCZ-UHFFFAOYSA-N 0.000 description 1
- GEBLWCHKOUZVPE-KJLVKZSNSA-N CC(C)(C)/C=C/C(N(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound CC(C)(C)/C=C/C(N(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O GEBLWCHKOUZVPE-KJLVKZSNSA-N 0.000 description 1
- YRXIMPFOTQVOHG-UHFFFAOYSA-N CC(C)(C)OC(N(C)CC(O)=O)=O Chemical compound CC(C)(C)OC(N(C)CC(O)=O)=O YRXIMPFOTQVOHG-UHFFFAOYSA-N 0.000 description 1
- LZYIYXOBDITMTC-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)Oc(cccc1)c1Oc(cc1)cc(C)c1Nc1ccnc(Cl)c1C#N Chemical compound CC(C)(C)[Si](C)(C)Oc(cccc1)c1Oc(cc1)cc(C)c1Nc1ccnc(Cl)c1C#N LZYIYXOBDITMTC-UHFFFAOYSA-N 0.000 description 1
- MQLNQYVZVZHRDH-UHFFFAOYSA-N CC(C)C1COCCC1 Chemical compound CC(C)C1COCCC1 MQLNQYVZVZHRDH-UHFFFAOYSA-N 0.000 description 1
- JWCCROHQQVDFJQ-LJQANCHMSA-N CC(C)N(CC1)C[C@@H]1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O Chemical compound CC(C)N(CC1)C[C@@H]1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O JWCCROHQQVDFJQ-LJQANCHMSA-N 0.000 description 1
- ACHPFHPCNZJGHB-GFCCVEGCSA-N CC(C)N(c1c(c(N2)c(C(N[C@H](CCC3)CN3C(C=C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound CC(C)N(c1c(c(N2)c(C(N[C@H](CCC3)CN3C(C=C)=O)=O)[s]3)c3ncc1)C2=O ACHPFHPCNZJGHB-GFCCVEGCSA-N 0.000 description 1
- HVOGVXMOKNUJIN-SNVBAGLBSA-N CC(C)N(c1c(c(N2)c(C(N[C@H]3CNCCC3)=O)[s]3)c3ncc1)C2=O Chemical compound CC(C)N(c1c(c(N2)c(C(N[C@H]3CNCCC3)=O)[s]3)c3ncc1)C2=O HVOGVXMOKNUJIN-SNVBAGLBSA-N 0.000 description 1
- MRGRJZRLUIYMFV-QGZVFWFLSA-N CC(C)c(cc1)cc(C)c1N(c1ccnc2c1c(N1)c(C(N[C@H]3CN(C)CCC3)=O)[s]2)C1=O Chemical compound CC(C)c(cc1)cc(C)c1N(c1ccnc2c1c(N1)c(C(N[C@H]3CN(C)CCC3)=O)[s]2)C1=O MRGRJZRLUIYMFV-QGZVFWFLSA-N 0.000 description 1
- DSHNFSVYLPQASU-UHFFFAOYSA-N CC(C1)COCCN1[Rh] Chemical compound CC(C1)COCCN1[Rh] DSHNFSVYLPQASU-UHFFFAOYSA-N 0.000 description 1
- LEYYJQRDMFRANK-ZVAWYAOSSA-N CC(C1)NCC[C@@H]1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O Chemical compound CC(C1)NCC[C@@H]1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O LEYYJQRDMFRANK-ZVAWYAOSSA-N 0.000 description 1
- TYEBDNNFWBEQTL-UHFFFAOYSA-N CC(CCCC1)CN1[Rh] Chemical compound CC(CCCC1)CN1[Rh] TYEBDNNFWBEQTL-UHFFFAOYSA-N 0.000 description 1
- SNJOCPFFSSPPKE-LYBHJNIJSA-N CC(Nc1c(C(N[I](CCC2)CN2C(/C(/C#N)=C/C(C)(C)C)=O)=O)[s]c2c1c1ccn2)N1c(cc1)c(C)cc1Oc1ccccc1 Chemical compound CC(Nc1c(C(N[I](CCC2)CN2C(/C(/C#N)=C/C(C)(C)C)=O)=O)[s]c2c1c1ccn2)N1c(cc1)c(C)cc1Oc1ccccc1 SNJOCPFFSSPPKE-LYBHJNIJSA-N 0.000 description 1
- JFAQXDWDLNKSEL-UHFFFAOYSA-N CC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3c4[o]ccc4ccc3)c11)c1NC2=O)=O Chemical compound CC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3c4[o]ccc4ccc3)c11)c1NC2=O)=O JFAQXDWDLNKSEL-UHFFFAOYSA-N 0.000 description 1
- SQMGOSDOXPKMMM-FPYGCLRLSA-N CC1(COC1)/C=C(/C(C)=O)\C#N Chemical compound CC1(COC1)/C=C(/C(C)=O)\C#N SQMGOSDOXPKMMM-FPYGCLRLSA-N 0.000 description 1
- OVRKATYHWPCGPZ-UHFFFAOYSA-N CC1CCOCC1 Chemical compound CC1CCOCC1 OVRKATYHWPCGPZ-UHFFFAOYSA-N 0.000 description 1
- JEGMWWXJUXDNJN-UHFFFAOYSA-N CC1CNCCC1 Chemical compound CC1CNCCC1 JEGMWWXJUXDNJN-UHFFFAOYSA-N 0.000 description 1
- WWYUTIGZIMZTMK-MRXNPFEDSA-N CCC(N(CC1)C[C@@H]1NC(c([s]c1nccc(N2c3ccc(CC)cc3C)c11)c1NC2=O)=O)=O Chemical compound CCC(N(CC1)C[C@@H]1NC(c([s]c1nccc(N2c3ccc(CC)cc3C)c11)c1NC2=O)=O)=O WWYUTIGZIMZTMK-MRXNPFEDSA-N 0.000 description 1
- QRMODIMVGFAYRL-UHFFFAOYSA-N CCC(N(CCC1)CC1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)=O Chemical compound CCC(N(CCC1)CC1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)=O QRMODIMVGFAYRL-UHFFFAOYSA-N 0.000 description 1
- DLEWDCPFCNLJEY-UHFFFAOYSA-N CCC(N1CCOCC1)=O Chemical compound CCC(N1CCOCC1)=O DLEWDCPFCNLJEY-UHFFFAOYSA-N 0.000 description 1
- MIPBQRXIUYPRRF-UHFFFAOYSA-N CCCC(N(CC1)CC1NC(c([s]c1nccc(N2c(cc3)c(C)c(F)c3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound CCCC(N(CC1)CC1NC(c([s]c1nccc(N2c(cc3)c(C)c(F)c3Oc3ccccc3)c11)c1NC2=O)=O)=O MIPBQRXIUYPRRF-UHFFFAOYSA-N 0.000 description 1
- WGIWCZQDMLHWRC-UHFFFAOYSA-N CCCN(CC1)CCN1[Rh] Chemical compound CCCN(CC1)CCN1[Rh] WGIWCZQDMLHWRC-UHFFFAOYSA-N 0.000 description 1
- GMWOIURKQPTGNF-UHFFFAOYSA-N CCCN(CCN1)C1=O Chemical compound CCCN(CCN1)C1=O GMWOIURKQPTGNF-UHFFFAOYSA-N 0.000 description 1
- CJKOXWAXWWWNKB-MRVPVSSYSA-N CCCN1[C@H](C)COCC1 Chemical compound CCCN1[C@H](C)COCC1 CJKOXWAXWWWNKB-MRVPVSSYSA-N 0.000 description 1
- PYGVAJIWHCWXEY-SFYZADRCSA-N CCC[C@@H](C)[C@](C)(CI)N Chemical compound CCC[C@@H](C)[C@](C)(CI)N PYGVAJIWHCWXEY-SFYZADRCSA-N 0.000 description 1
- ANQIXIASCBMKTH-VRUMLPLGSA-N CCNC(CCCC(NCCCOCCOCCOCCCNC(CCCC[C@H]([C@H]1N2)SC[C@@H]1NC2=O)=O)=O)=O Chemical compound CCNC(CCCC(NCCCOCCOCCOCCCNC(CCCC[C@H]([C@H]1N2)SC[C@@H]1NC2=O)=O)=O)=O ANQIXIASCBMKTH-VRUMLPLGSA-N 0.000 description 1
- VBSQYKNNGGBUTA-OAHLLOKOSA-N CCOc(cc1)cc(C)c1N(c1ccnc2c1c(N1)c(C(N[C@H]3CN(C)CCC3)=O)[s]2)C1=O Chemical compound CCOc(cc1)cc(C)c1N(c1ccnc2c1c(N1)c(C(N[C@H]3CN(C)CCC3)=O)[s]2)C1=O VBSQYKNNGGBUTA-OAHLLOKOSA-N 0.000 description 1
- LOFUJZDAMYUZEB-LJQANCHMSA-N CC[C@H](CNC)[N](C)(C(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)#C Chemical compound CC[C@H](CNC)[N](C)(C(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)#C LOFUJZDAMYUZEB-LJQANCHMSA-N 0.000 description 1
- APNLDCNOWAGQNC-CYBMUJFWSA-N CN(C)c1cc(N(c2c(c(N3)c(C(N[C@H]4CNCCC4)=O)[s]4)c4ncc2)C3=O)ccc1 Chemical compound CN(C)c1cc(N(c2c(c(N3)c(C(N[C@H]4CNCCC4)=O)[s]4)c4ncc2)C3=O)ccc1 APNLDCNOWAGQNC-CYBMUJFWSA-N 0.000 description 1
- BIZMBGNRCBJIBG-LLVKDONJSA-N CN(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c3c4OCOc4ccc3Cl)c11)c1NC2=O)=O Chemical compound CN(CCC1)C[C@@H]1NC(c([s]c1nccc(N2c3c4OCOc4ccc3Cl)c11)c1NC2=O)=O BIZMBGNRCBJIBG-LLVKDONJSA-N 0.000 description 1
- KONGHAQHCRMKEM-LEWJYISDSA-N C[C@@H](COC)C(N(CCC1)C[C@@H]1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)=O Chemical compound C[C@@H](COC)C(N(CCC1)C[C@@H]1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)=O KONGHAQHCRMKEM-LEWJYISDSA-N 0.000 description 1
- UJQZTMFRMLEYQN-LURJTMIESA-N C[C@@H]1COCCC1 Chemical compound C[C@@H]1COCCC1 UJQZTMFRMLEYQN-LURJTMIESA-N 0.000 description 1
- XSYQVGDVKYEVAB-QNSVNVJESA-N C[C@H](CC1)NCC1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O Chemical compound C[C@H](CC1)NCC1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O XSYQVGDVKYEVAB-QNSVNVJESA-N 0.000 description 1
- UJQZTMFRMLEYQN-ZCFIWIBFSA-N C[C@H]1COCCC1 Chemical compound C[C@H]1COCCC1 UJQZTMFRMLEYQN-ZCFIWIBFSA-N 0.000 description 1
- HDXNBSGQBCOARN-LJQANCHMSA-N Cc(c(C)c(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CC3)CN3C(C=C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(c(C)c(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CC3)CN3C(C=C)=O)=O)[s]3)c3ncc1)C2=O HDXNBSGQBCOARN-LJQANCHMSA-N 0.000 description 1
- WVVYZLFSVKMWQZ-UHFFFAOYSA-N Cc(c(N(c1ccnc2c1c(N1)c(C(O)=O)[s]2)C1=O)ccc1)c1Oc1ccccc1 Chemical compound Cc(c(N(c1ccnc2c1c(N1)c(C(O)=O)[s]2)C1=O)ccc1)c1Oc1ccccc1 WVVYZLFSVKMWQZ-UHFFFAOYSA-N 0.000 description 1
- UAEQTZYHMLKNGU-CQSZACIVSA-N Cc(cc(cc1)OC)c1N(c1c(c(N2)c(C(N[C@H]3CN(C)CCC3)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)OC)c1N(c1c(c(N2)c(C(N[C@H]3CN(C)CCC3)=O)[s]3)c3ncc1)C2=O UAEQTZYHMLKNGU-CQSZACIVSA-N 0.000 description 1
- PQJTZWMGPDMULZ-UHFFFAOYSA-N Cc(cc(cc1)OC2C=CC=CC2)c1N(c1c(c(N2)c(C(NC3CN(C)C3)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)OC2C=CC=CC2)c1N(c1c(c(N2)c(C(NC3CN(C)C3)=O)[s]3)c3ncc1)C2=O PQJTZWMGPDMULZ-UHFFFAOYSA-N 0.000 description 1
- JRYOLMRBPBHWKI-QGZVFWFLSA-N Cc(cc(cc1)Oc(c(F)ccc2)c2F)c1N(c1ccnc2c1c(N1)c(C(N[C@H](CCC3)CN3C(C=C)=O)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc(c(F)ccc2)c2F)c1N(c1ccnc2c1c(N1)c(C(N[C@H](CCC3)CN3C(C=C)=O)=O)[s]2)C1=O JRYOLMRBPBHWKI-QGZVFWFLSA-N 0.000 description 1
- MTEHVAPFLGTMBQ-QGZVFWFLSA-N Cc(cc(cc1)Oc(cccc2)c2O)c1N(c1ccnc2c1c(N1)c(C(N[C@H]3CN(C)CCC3)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc(cccc2)c2O)c1N(c1ccnc2c1c(N1)c(C(N[C@H]3CN(C)CCC3)=O)[s]2)C1=O MTEHVAPFLGTMBQ-QGZVFWFLSA-N 0.000 description 1
- KHOVXXGEXBPJPI-UHFFFAOYSA-N Cc(cc(cc1)Oc(cccc2)c2OC)c1N(c1ccnc2c1c(N1)c(C(O)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc(cccc2)c2OC)c1N(c1ccnc2c1c(N1)c(C(O)=O)[s]2)C1=O KHOVXXGEXBPJPI-UHFFFAOYSA-N 0.000 description 1
- PZSQEDKYHZMUKK-IBGZPJMESA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(CNC[C@H]3NCCCC3)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(CNC[C@H]3NCCCC3)=O)[s]3)c3ncc1)C2=O PZSQEDKYHZMUKK-IBGZPJMESA-N 0.000 description 1
- KNBNTDHHCQJMQZ-UHFFFAOYSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(NC(C3)CN3C(C=C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(NC(C3)CN3C(C=C)=O)=O)[s]3)c3ncc1)C2=O KNBNTDHHCQJMQZ-UHFFFAOYSA-N 0.000 description 1
- DBXGLNJVFGRXGX-UHFFFAOYSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(NC(C3)CN3C(CCOC)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(NC(C3)CN3C(CCOC)=O)=O)[s]3)c3ncc1)C2=O DBXGLNJVFGRXGX-UHFFFAOYSA-N 0.000 description 1
- KDSZISYAIQDWHZ-RXVVDRJESA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@@H](CN(C)C3)[C@H]3O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@@H](CN(C)C3)[C@H]3O)=O)[s]3)c3ncc1)C2=O KDSZISYAIQDWHZ-RXVVDRJESA-N 0.000 description 1
- UVGJUNVKDNTOOR-IAGOWNOFSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](C3)CNC[C@@H]3F)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](C3)CNC[C@@H]3F)=O)[s]3)c3ncc1)C2=O UVGJUNVKDNTOOR-IAGOWNOFSA-N 0.000 description 1
- RPILJJOLVAWFLV-UHFFFAOYSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(NC(CCC3)CCN3C#N)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(NC(CCC3)CCN3C#N)=O)[s]2)C1=O RPILJJOLVAWFLV-UHFFFAOYSA-N 0.000 description 1
- YZYCMFOFTVTZSI-UHFFFAOYSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(NC3CCN(C)CCC3)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(NC3CCN(C)CCC3)=O)[s]2)C1=O YZYCMFOFTVTZSI-UHFFFAOYSA-N 0.000 description 1
- MHHAFNXGJYUPLJ-UHFFFAOYSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(NC3COCCN(C)C3)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(NC3COCCN(C)C3)=O)[s]2)C1=O MHHAFNXGJYUPLJ-UHFFFAOYSA-N 0.000 description 1
- IZHQYJYMIITLIC-UHFFFAOYSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(NCCN(CCN3)C3=O)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(NCCN(CCN3)C3=O)=O)[s]2)C1=O IZHQYJYMIITLIC-UHFFFAOYSA-N 0.000 description 1
- UVGJUNVKDNTOOR-DLBZAZTESA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(N[C@H](C3)CNC[C@H]3F)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(N[C@H](C3)CNC[C@H]3F)=O)[s]2)C1=O UVGJUNVKDNTOOR-DLBZAZTESA-N 0.000 description 1
- ITXAIRSLSJYBMV-MRXNPFEDSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(N[C@H]3COCC3)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(N[C@H]3COCC3)=O)[s]2)C1=O ITXAIRSLSJYBMV-MRXNPFEDSA-N 0.000 description 1
- ONLGKFAEHRRSEQ-GOSISDBHSA-N Cc(nc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)CN3C(CC#N)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(nc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)CN3C(CC#N)=O)=O)[s]3)c3ncc1)C2=O ONLGKFAEHRRSEQ-GOSISDBHSA-N 0.000 description 1
- URUJNELIHBQRBW-QGZVFWFLSA-N Cc1cc(Oc2ncccc2)ccc1N(c1ccnc2c1c(N1)c(C(N[C@H]3CN(C)CCC3)=O)[s]2)C1=O Chemical compound Cc1cc(Oc2ncccc2)ccc1N(c1ccnc2c1c(N1)c(C(N[C@H]3CN(C)CCC3)=O)[s]2)C1=O URUJNELIHBQRBW-QGZVFWFLSA-N 0.000 description 1
- GFKFCNCBIFBYRO-UHFFFAOYSA-N Cc1ccccc1N(c1ccnc2c1c(N1)c(C(O)=O)[s]2)C1=O Chemical compound Cc1ccccc1N(c1ccnc2c1c(N1)c(C(O)=O)[s]2)C1=O GFKFCNCBIFBYRO-UHFFFAOYSA-N 0.000 description 1
- KLIUVAZOOAMXCH-AAGJOFLKSA-N N#C/C(/C(N(CCC1)C[C@@H]1NC(c([s]c1c2c(N3c(c4c(cc5)OCO4)c5Cl)ccn1)c2NC3=O)=O)=O)=C\C1CC1 Chemical compound N#C/C(/C(N(CCC1)C[C@@H]1NC(c([s]c1c2c(N3c(c4c(cc5)OCO4)c5Cl)ccn1)c2NC3=O)=O)=O)=C\C1CC1 KLIUVAZOOAMXCH-AAGJOFLKSA-N 0.000 description 1
- SXUJGIFYFLFJTO-UHFFFAOYSA-N O=C(Nc1c[s]2)Nc3c1c2ncc3 Chemical compound O=C(Nc1c[s]2)Nc3c1c2ncc3 SXUJGIFYFLFJTO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265780P | 2015-12-10 | 2015-12-10 | |
| US62/265,780 | 2015-12-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201734020A TW201734020A (zh) | 2017-10-01 |
| TWI739779B true TWI739779B (zh) | 2021-09-21 |
Family
ID=57681785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105140759A TWI739779B (zh) | 2015-12-10 | 2016-12-09 | 布魯頓氏酪胺酸激酶抑制劑及其使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10689396B2 (enExample) |
| EP (1) | EP3386992B1 (enExample) |
| JP (2) | JP7110097B2 (enExample) |
| KR (1) | KR20180094514A (enExample) |
| CN (2) | CN113105475B (enExample) |
| AR (1) | AR107041A1 (enExample) |
| AU (1) | AU2016366546B2 (enExample) |
| BR (1) | BR112018011525B1 (enExample) |
| CA (1) | CA3007993C (enExample) |
| EA (1) | EA038031B1 (enExample) |
| IL (1) | IL259862B (enExample) |
| JO (1) | JO3793B1 (enExample) |
| MX (1) | MX386700B (enExample) |
| TW (1) | TWI739779B (enExample) |
| UY (1) | UY37016A (enExample) |
| WO (1) | WO2017100668A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3003987B2 (ja) | 1996-08-20 | 2000-01-31 | 篠▲崎▼ 晴彦 | 合成樹脂管内に施設されるケーブルの支持装置及びそのケーブル支持具を取付ける方法 |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| WO2018170220A1 (en) * | 2017-03-15 | 2018-09-20 | Janssen Sciences Ireland Uc | Methods of selective aryl- and heteroaryl-nitrogen bond formation |
| CN110028525A (zh) * | 2018-04-13 | 2019-07-19 | 太仓运通新材料科技有限公司 | 一种2-氟磷酰基乙酸三乙酯的合成方法 |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP4218934B1 (en) * | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| CA3116141C (en) | 2018-12-06 | 2023-09-05 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
| CN114401957B (zh) * | 2019-09-04 | 2023-11-21 | 正大天晴药业集团股份有限公司 | 一种喹唑啉衍生物的制备方法及其结晶 |
| CN111635368B (zh) * | 2020-06-12 | 2021-06-29 | 东莞市东阳光仿制药研发有限公司 | 一种胺化合物的制备方法 |
| MX2023014435A (es) | 2021-06-04 | 2024-03-08 | Janssen Pharmaceutica Nv | Inhibidores de la tirosina quinasa de bruton y métodos de su uso. |
| MX2023015147A (es) * | 2021-06-30 | 2024-04-01 | Janssen Pharmaceutica Nv | Inhibidores de la tirosina quinasa de bruton y métodos de su uso. |
| CN114478346A (zh) * | 2021-12-31 | 2022-05-13 | 和鼎（南京）医药技术有限公司 | 一种制备乌帕替尼中间体的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007092879A2 (en) * | 2006-02-08 | 2007-08-16 | Janssen Pharmaceutica, N.V. | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3112415A1 (de) | 1981-03-28 | 1982-10-07 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden |
| US5430150A (en) | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
| US5300478A (en) | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
| AU2005284796A1 (en) | 2004-09-15 | 2006-03-23 | Janssen Pharmaceutica, N.V. | Thiazolopyridine kinase inhibitors |
| US7579356B2 (en) | 2005-05-04 | 2009-08-25 | Janssen Pharmaceutica Nv | Thia-tetraazaacenaphthylene kinase inhibitors |
| US7605154B2 (en) | 2005-08-08 | 2009-10-20 | Janssen Pharmaceutica N.V. | Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| WO2010056875A1 (en) * | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
| WO2011133609A2 (en) | 2010-04-19 | 2011-10-27 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of btk inhibitors |
| FR2978441A1 (fr) | 2011-07-25 | 2013-02-01 | Diverchim | Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques |
| EP2970291B1 (en) | 2013-03-15 | 2022-05-11 | Janssen Pharmaceutica, N.V. | Processes and intermediates for preparing a medicament |
| HRP20181109T1 (hr) * | 2013-12-11 | 2018-11-02 | Biogen Ma Inc. | Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji |
| JO3794B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| WO2018103058A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| WO2018103060A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
-
2016
- 2016-12-08 JO JOP/2016/0257A patent/JO3793B1/ar active
- 2016-12-09 CN CN202110404344.9A patent/CN113105475B/zh active Active
- 2016-12-09 MX MX2018007084A patent/MX386700B/es unknown
- 2016-12-09 BR BR112018011525-8A patent/BR112018011525B1/pt active IP Right Grant
- 2016-12-09 TW TW105140759A patent/TWI739779B/zh not_active IP Right Cessation
- 2016-12-09 EA EA201891379A patent/EA038031B1/ru unknown
- 2016-12-09 CN CN201680072147.9A patent/CN109071563A/zh active Pending
- 2016-12-09 EP EP16820107.7A patent/EP3386992B1/en active Active
- 2016-12-09 UY UY0001037016A patent/UY37016A/es unknown
- 2016-12-09 US US15/374,945 patent/US10689396B2/en active Active
- 2016-12-09 JP JP2018529982A patent/JP7110097B2/ja active Active
- 2016-12-09 WO PCT/US2016/065964 patent/WO2017100668A1/en not_active Ceased
- 2016-12-09 CA CA3007993A patent/CA3007993C/en active Active
- 2016-12-09 KR KR1020187019519A patent/KR20180094514A/ko active Pending
- 2016-12-09 AU AU2016366546A patent/AU2016366546B2/en not_active Ceased
- 2016-12-12 AR ARP160103788A patent/AR107041A1/es unknown
-
2018
- 2018-06-07 IL IL259862A patent/IL259862B/en unknown
-
2019
- 2019-05-15 US US16/413,317 patent/US10822348B2/en active Active
- 2019-05-15 US US16/413,417 patent/US10800792B2/en active Active
-
2022
- 2022-07-20 JP JP2022115945A patent/JP7471348B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007092879A2 (en) * | 2006-02-08 | 2007-08-16 | Janssen Pharmaceutica, N.V. | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| EA038031B1 (ru) | 2021-06-25 |
| IL259862B (en) | 2022-04-01 |
| UY37016A (es) | 2017-06-30 |
| JP7471348B2 (ja) | 2024-04-19 |
| JP2022141851A (ja) | 2022-09-29 |
| MX2018007084A (es) | 2018-11-09 |
| CN113105475A (zh) | 2021-07-13 |
| TW201734020A (zh) | 2017-10-01 |
| US10689396B2 (en) | 2020-06-23 |
| WO2017100668A1 (en) | 2017-06-15 |
| KR20180094514A (ko) | 2018-08-23 |
| US20190284204A1 (en) | 2019-09-19 |
| BR112018011525A2 (pt) | 2018-11-21 |
| AR107041A1 (es) | 2018-03-14 |
| US20170283431A1 (en) | 2017-10-05 |
| US20190284203A1 (en) | 2019-09-19 |
| CN113105475B (zh) | 2022-09-09 |
| JP7110097B2 (ja) | 2022-08-01 |
| IL259862A (en) | 2018-07-31 |
| JO3793B1 (ar) | 2021-01-31 |
| AU2016366546A1 (en) | 2018-05-31 |
| JP2018536684A (ja) | 2018-12-13 |
| US10822348B2 (en) | 2020-11-03 |
| CN109071563A (zh) | 2018-12-21 |
| BR112018011525B1 (pt) | 2023-10-24 |
| EP3386992A1 (en) | 2018-10-17 |
| MX386700B (es) | 2025-03-19 |
| EP3386992B1 (en) | 2019-11-27 |
| EA201891379A1 (ru) | 2018-12-28 |
| CA3007993C (en) | 2024-01-16 |
| US10800792B2 (en) | 2020-10-13 |
| CA3007993A1 (en) | 2017-06-15 |
| AU2016366546B2 (en) | 2021-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI874443B (zh) | KRas G12D抑制劑 | |
| CN113105475B (zh) | 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法 | |
| TWI729047B (zh) | 布魯頓氏（ｂｒｕｔｏｎ）酪胺酸激酶抑制劑及其使用方法 | |
| CN113272301A (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
| CN116670143A (zh) | 囊性纤维化跨膜传导调控因子的调节剂 | |
| JP2017518276A (ja) | ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物 | |
| TW201605859A (zh) | 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌 | |
| TW201446752A (zh) | Ｐｈｄ之６－（５-羥基-１ｈ-吡唑-１-基）菸鹼醯胺抑制劑 | |
| KR20230123471A (ko) | 화합물, 조성물 및 방법 | |
| CN113563311A (zh) | 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物 | |
| WO2024125532A1 (zh) | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 | |
| WO2022199599A1 (zh) | 丙烯酰基取代的化合物、包含其的药物组合物及其用途 | |
| WO2018103058A1 (en) | Inhibitors of bruton's tyrosine kinase and methods of their use | |
| HK40062758A (en) | Diarylthiohydantoin compound as androgen receptor antagonist | |
| HK40052204B (en) | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | |
| HK40052204A (en) | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | |
| HK40097906A (en) | Compounds, compositions, and methods | |
| HK40076948B (en) | Kras g12d inhibitors | |
| HK40076948A (en) | Kras g12d inhibitors | |
| HK40019862A (en) | Diarylthiohydantoin compound as androgen receptor antagonist | |
| HK40019862B (en) | Diarylthiohydantoin compound as androgen receptor antagonist | |
| HK40048952A (en) | Heterocyclic compound, intermediate, preparation method therefor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |